The Transfusion Dependent Thalassaemia Management Market is set to garner a value of USD 10 Million in 2023, with projections indicating it will grow to USD 17.91 Million by 2033, reflecting a robust CAGR of 6% during the forecast period from 2023 to 2033. This growth follows a historical CAGR of 4% from 2018 to 2022, highlighting an increasing focus on the management and treatment of this genetic blood disorder.
Thalassemia, a hereditary condition affecting approximately 4.4 out of every 10,000 live births globally, results from inherited gene mutations that can affect both males and females equally, as it follows an autosomal pattern of inheritance. The rising prevalence of thalassemia, coupled with increasing awareness and advancements in therapeutic options, is driving the demand for effective management solutions. As research and innovation in treatment continue to evolve, the Transfusion Dependent Thalassaemia Management Market is positioned for significant growth in the coming years.
2018 to 2022 Transfusion Dependent Thalassaemia Management Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Transfusion Dependent Thalassaemia Management reflected a value of 4% during the historical period, 2018 to 2022.
A series of international-level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering effective ways for Transfusion Dependent Thalassaemia Management.
According to the National Center on Birth Defects and Developmental Disabilities, thalassemia affects at least 1,000 people in the United States of America. The market’s growth is also attributed to the factors such as growing disease prevalence, a rise in lifestyle-associated concerns, and technological advancements. Furthermore, the increasing incidence of thalassemia patients and increasing research and development investments are propelling immense growth.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights into key factors driving demand for Transfusion Dependent Thalassaemia Management. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of thalassemia is fuelling market growth. Thus, the market for Transfusion Dependent Thalassaemia Management is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Market Competition
Key players in the Transfusion Dependent Thalassaemia Management Market are Celgene Corporation, BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Sangamo Therapeutics, Orchard Therapeutics, CRISPR Therapeutics, and DisperSol Technologies among other global players.
- In November 2022, the Centers for Disease Control and Prevention (CDC) launched a Thalassemia Healthcare Provider Resource Toolkit. This free toolkit is filled with free resources for providers caring for people living with thalassemia. It includes Continuing Medical Education Offerings and Webinars, Scientific Articles and Features, CDC Activities Related to Transfusion Complications in Thalassemia, Resources on Newborn Screening, Thalassemia Treatment Centers, Resources for Thalassemia Care, Treatment, and Management, and so on.
- In August 2022, the USA Food and Drug Administration approved Zynteglo (Betibeglogene auto excel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.
Key Companies Profiled
- Sigma-Aldrich. BD
- Enzo Life Sciences
- Creative Diagnostics
- Thermo Fisher Scientific
- Epitope Diagnostics Inc.
- R&D Systems
- QED Bioscience Inc
- ACROBiosystems.
Key Segments Profiled in the Transfusion Dependent Thalassaemia Management Industry Survey
Therapy:
- Iron Chelating Drugs
- Erythroid Maturation Agents
- Stem Cell Therapy
- Others
End-User:
- Hospital
- Homecare
- Specialty Clinics
- Others
Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube